Structure-activity relationships of astemizole derivatives for inhibition of store operated Ca2+ channels and exocytosis

European Journal of Pharmacology

Volumn 350, Issue 2-3, 1998, Pages 353-361

  Fischer, Marcel J E ^a   Paulussen, Jeannette J C ^a   Tollenaere, Jan P ^a   De Mol, Nico J ^a   Janssen, Lambert H M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Antiallergic; Astemizole; Ca2+ channel; Exocytosis; RBL 2H3; Store operated

Indexed keywords

ANTIGEN; ASTEMIZOLE; BENZIMIDAZOLE; BETA N ACETYLHEXOSAMINIDASE; CALCIUM 45; CALCIUM CHANNEL; CALCIUM ION; DRUG ANALOG; FC RECEPTOR; THAPSIGARGIN;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CELL MEMBRANE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; EXOCYTOSIS; HYDROPHOBICITY; LIPOPHILICITY; MAST CELL; MEMBRANE STABILIZATION; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ASTEMIZOLE; BETA-N-ACETYLHEXOSAMINIDASE; CALCIUM CHANNELS; CALCIUM RADIOISOTOPES; CATTLE; CELLS, CULTURED; ERYTHROCYTE MEMBRANE; ERYTHROCYTES; EXOCYTOSIS; HEMOLYSIS; HISTAMINE H1 ANTAGONISTS; HYPOTONIC SOLUTIONS; INDICATORS AND REAGENTS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032486116     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00270-2     Document Type: Article

References (30)

1. 1-antagonist astemizole. Arzneimittelforschung-Drug Res. 33:1983;381-388.
2. Berridge M.J. Capacitative calcium entry. Biochem. J. 312:1995;1-11.
3. 2+ current, IL-2 production and activation in T lymphocytes. Br. J. Pharmacol. 113:1994;861-868.
4. 2+ ions. FEBS Lett. 310:1992;123-128.
5. 1-receptor antagonists). J. Allergy Clin. Immunol. 90:1992;705-715.
6. Fanger C.M., Hoth M., Crabtree G.R., Lewis R.S. Characterization of T cell mutants with defects in capacitative calcium entry: genetic evidence for the physiological roles of CRAC channels. J. Cell Biol. 131:1995;655-667.
7. Felder C.C., Singer-Lahat D., Mathes C. Voltage-independent calcium channels - regulation by receptors and intracellular calcium stores. Biochem. Pharmacol. 48:1994;1997-2004.
8. 1-antagonist derived anti-allergic drugs: relation to lipophilicity and membrane effects. Inflamm. Res. 44:1995;92-97.
9. Fischer M.J.E., Paulussen J.J.C., Kok-van Esterik J.A.E., Van der Heijden V.S., De Mol N.J., Janssen L.H.M. Effects of the antiallergics astemizole and norastemizole on FcεRI-mediated signal transduction. Eur. J. Pharmacol. 322:1997;97-105.
10. 2+ influx. Biochem. Pharmacol. 55:1998;1255-1262.
11. Franzius D., Hoth M., Penner R. Non-specific effects of calcium entry antagonists in mast cells. Eur. J. Physiol. 428:1994;433-438.
12. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:1985;3440-3450.
13. Hintze, J.L. (Ed.), 1987. NCSS Version 5.01, Number Cruncher Statistical Systems, 1987. Kaysville, UT.
14. Hoth M., Penner R. Calcium release-activated calcium current in rat mast cells. J. Physiol. 465:1993;359-386.
15. Hoth M. Calcium and barium permeation through calcium release-activated calcium (CRAC) channels. Eur. J. Physiol. 430:1995;315-322.
16. Janssens F., Torremans J., Janssen M., Stokbroekx R.A., Luyckx M., Janssen P.A.J. New antihistaminic N-heterocyclic 4-piperidinamines: 1. Synthesis and antihistaminic activity of N-(4-piperidinyl)-1H-benzimidazol-2-amines. J. Med. Chem. 28:1985;1925-1933.
17. Janssens F., Torremans J., Janssen M., Stokbroekx R.A., Luyckx M., Janssen P.A.J. New antihistaminic N-heterocyclic 4-piperidinamines: 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amines. J. Med. Chem. 28:1985;1934-1943.
18. Janssens F., Torremans J., Janssen M., Stokbroekx R.A., Luyckx M., Janssen P.A.J. New antihistaminic N-heterocyclic 4-piperidinamines: 3. Synthesis and antihistaminic activity of N-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-2-amines. J. Med. Chem. 28:1985;1943-1947.
19. Kamei C., Mio M., Izushi K., Kitazumi K., Tsujimoto S., Fujisawa K., Adachi Y., Tasaka K. Antiallergic effects of major metabolites of astemizole in rats and guinea pigs. Arzneimittelforschung-Drug Res. 41:1991;932-936.
20. Kothekar V., Gupta D. 200 Picosecond molecular dynamics simulation of interaction of nifedipine with 1-2 dimyristoyl phosphatidylcholine membrane. Indian J. Biochem. Biophys. 31:1994;24-30.
21. Lau H.Y.A., Pearce F.L. Effects of antihistamines on isolated rat peritoneal mast cells and on model membrane systems. Agents Actions. 29:1990;151-161.
22. Miyazaki J., Hideg K., Marsh D. Interfacial ionization and partitioning of membrane-bound local anaesthetics. Biochim. Biophys. Acta. 1103:1992;62-68.
23. Paulussen J.J.C., Fischer M.J.E., Roelofsen E.P.W., Horbach D.A., De Mol N.J., Janssen L.H.M. Oxatomide and derivatives as inhibitors of mediator release from a mast cell model; structure activity relationships. Arzneimittelforschung-Drug Res. 46:1996;496-501.
24. Richards D.M., Brogden R.N., Heel R.C., Speight T.M., Avery G.S. Astemizole, a review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 28:1984;38-61.
25. Sainz M.C., Chantres J.R., Elorza B., Elorza M.A. DSC study of the action of phenylbutazone on DMPC and DPPC bilayers. Int. J. Pharm. 89:1993;183-190.
26. Tasaka K., Akagi M., Izushi K., Mio M. Antiallergic effects of astemizole on immediate type hypersensitivity reactions. Methods Find. Exp. Clin. Pharmacol. 12:1990;531-539.
27. 2+-ATPase. Proc. Natl. Acad. Sci. USA. 87:1990;2466-2470.
28. Thomas P.G., Seelig J. Binding of the calcium antagonist flunarizine to phosphatidylcholine bilayers - charge effects and thermodynamics. Biochem. J. 291:1993;397-402.
29. 1-antihistaminic compound. Arch. Int. Pharmacodyn. 251:1981;39-51.
30. Zhang L., McCloskey M.A. Immunoglobulin E-receptor-activated calcium conductance in rat mast cells. J. Phys. 483:1995;59-66.